News | September 01, 2021
Shilpa Medicare receives approval for 2-Deoxy-2-Glucose powder
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Aashka Hospitals has entered into a non-binding agreement for its proposed tie-up with Vaidehi—Backbone hospital, Rajkot
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
The drug is also intended for the treatment of glioblastoma multiforme
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Subscribe To Our Newsletter & Stay Updated
